Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)Andreas Wollenberg, Marius Ardeleanu, Andrew Blauvelt et al.|British Journal of Dermatology|2019Cited by 142